Cronos Group Reports 2023 Second Quarter Results
Industry-leading balance sheet with $841 million in cash and short-term investments Increased 2023 operating expense…
News
Cronos Group Reports 2023 Second Quarter Results
Industry-leading balance sheet with $841 million in cash and short-term investments Increased 2023 operating expense…
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced…
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced…
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral…
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral…
Harvard Bioscience Announces Second Quarter 2023 Financial Results
Q2 Revenues of $28.8 million Q2 GAAP operating income $0.8 million, adjusted operating income $3.6…
Harvard Bioscience Announces Second Quarter 2023 Financial Results
Q2 Revenues of $28.8 million Q2 GAAP operating income $0.8 million, adjusted operating income $3.6…
SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023
Robust growth and efficient expense execution continues BOSTON and ROLLE, Switzerland, Aug. 08, 2023 (GLOBE…
SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023
Robust growth and efficient expense execution continues BOSTON and ROLLE, Switzerland, Aug. 08, 2023 (GLOBE…
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced…
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced…
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase…
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase…
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari TORONTO and HOUSTON,…
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari TORONTO and HOUSTON,…
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
Positive INTERCEPT-AD Phase 1 trial results announced in July 2023 demonstrate ACU193’s potential as a…
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
Positive INTERCEPT-AD Phase 1 trial results announced in July 2023 demonstrate ACU193’s potential as a…
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter…
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter…